EARN25

Biotech Stock Falls on Late-Stage Study

FibroGen's neuromuscular disorder therapy failed to meet expectations

Deputy Editor
Jun 7, 2023 at 10:29 AM
facebook X logo linkedin


FibroGen Inc (NASDAQ:FGEN) stock is sliding today, after the biotech company announced disappointing results from a late-stage trial of pamrevlumab, its experimental drug to treat patients with Duchenne muscular dystrophy. At last glance, FGEN was down 9% to trade at $17.02. 

The stock's 80-day moving average kept a cap on gains the last couple sessions, and the stock is now back below the $18 level, which provided a firm line of pressure for most of May. Year-over-year, the equity is up about 65%. 

It's also worth noting that short interest represents 6.2% of the stock's available float. It would take shorts over six days to cover their bets, at FGEN's average pace of trading. 

Short-term options traders have been much more bearish than usual, per the stock's Schaeffer's put/call open interest ratio (SOIR) of 1.20, which sits in the 100th percentile of readings from the past 12 months.

 
 

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!